H2N2V1, PubMed, Checkpoint, bibRecord, 000183

In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.

Identifieur interne : 000183 ( PubMed/Checkpoint ); précédent : 000182; suivant : 000184

In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.

Auteurs : Katrina Sleeman [États-Unis] ; Vasiliy P. Mishin ; Varough M. Deyde ; Yousuke Furuta ; Alexander I. Klimov ; Larisa V. Gubareva

Source :

Antimicrobial agents and chemotherapy [ 1098-6596 ] ; 2010.

RBID : pubmed:20350949

Descripteurs français

English descriptors

KwdEn :
- Amides (pharmacology), Animals, Antiviral Agents (pharmacology), Cell Line, Dogs, Drug Resistance, Viral, Humans, In Vitro Techniques, Influenza A Virus, H1N1 Subtype (drug effects), Influenza A Virus, H1N1 Subtype (physiology), Influenza A Virus, H2N2 Subtype (drug effects), Influenza A Virus, H2N2 Subtype (physiology), Influenza A Virus, H5N1 Subtype (drug effects), Influenza A Virus, H5N1 Subtype (physiology), Influenza A virus (drug effects), Influenza A virus (physiology), Influenza B virus (drug effects), Influenza B virus (physiology), Influenza, Human (drug therapy), Influenza, Human (virology), Microbial Sensitivity Tests, Pyrazines (pharmacology), Swine, Viral Plaque Assay, Virus Replication (drug effects).
MESH :
- chemical , pharmacology : Amides, Antiviral Agents, Pyrazines.
- drug effects : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H2N2 Subtype, Influenza A Virus, H5N1 Subtype, Influenza A virus, Influenza B virus, Virus Replication.
- drug therapy : Influenza, Human.
- physiology : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H2N2 Subtype, Influenza A Virus, H5N1 Subtype, Influenza A virus, Influenza B virus.
- virology : Influenza, Human.
- Animals, Cell Line, Dogs, Drug Resistance, Viral, Humans, In Vitro Techniques, Microbial Sensitivity Tests, Swine, Viral Plaque Assay.

Abstract

Favipiravir (T-705) has previously been shown to have a potent antiviral effect against influenza virus and some other RNA viruses in both cell culture and in animal models. Currently, favipiravir is undergoing clinical evaluation for the treatment of influenza A and B virus infections. In this study, favipiravir was evaluated in vitro for its ability to inhibit the replication of a representative panel of seasonal influenza viruses, the 2009 A(H1N1) strains, and animal viruses with pandemic (pdm) potential (swine triple reassortants, H2N2, H4N2, avian H7N2, and avian H5N1), including viruses which are resistant to the currently licensed anti-influenza drugs. All viruses were tested in a plaque reduction assay with MDCK cells, and a subset was also tested in both yield reduction and focus inhibition (FI) assays. For the majority of viruses tested, favipiravir significantly inhibited plaque formation at 3.2 muM (0.5 microg/ml) (50% effective concentrations [EC(50)s] of 0.19 to 22.48 muM and 0.03 to 3.53 microg/ml), and for all viruses, with the exception of a single dually resistant 2009 A(H1N1) virus, complete inhibition of plaque formation was seen at 3.2 muM (0.5 microg/ml). Due to the 2009 pandemic and increased drug resistance in circulating seasonal influenza viruses, there is an urgent need for new drugs which target influenza. This study demonstrates that favipiravir inhibits in vitro replication of a wide range of influenza viruses, including those resistant to currently available drugs.

DOI: 10.1128/AAC.01739-09
PubMed: 20350949

Affiliations:

États-Unis

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000204
to stream PubMed, to step Curation: 000204

Links to Exploration step

pubmed:20350949

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.</title>
<author><name sortKey="Sleeman, Katrina" sort="Sleeman, Katrina" uniqKey="Sleeman K" first="Katrina" last="Sleeman">Katrina Sleeman</name>
<affiliation wicri:level="1"><nlm:affiliation>Virus Surveillance and Diagnosis Branch, Influenza Division, National Center of Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329-4018, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Virus Surveillance and Diagnosis Branch, Influenza Division, National Center of Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329-4018</wicri:regionArea>
<wicri:noRegion>GA 30329-4018</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mishin, Vasiliy P" sort="Mishin, Vasiliy P" uniqKey="Mishin V" first="Vasiliy P" last="Mishin">Vasiliy P. Mishin</name>
</author>
<author><name sortKey="Deyde, Varough M" sort="Deyde, Varough M" uniqKey="Deyde V" first="Varough M" last="Deyde">Varough M. Deyde</name>
</author>
<author><name sortKey="Furuta, Yousuke" sort="Furuta, Yousuke" uniqKey="Furuta Y" first="Yousuke" last="Furuta">Yousuke Furuta</name>
</author>
<author><name sortKey="Klimov, Alexander I" sort="Klimov, Alexander I" uniqKey="Klimov A" first="Alexander I" last="Klimov">Alexander I. Klimov</name>
</author>
<author><name sortKey="Gubareva, Larisa V" sort="Gubareva, Larisa V" uniqKey="Gubareva L" first="Larisa V" last="Gubareva">Larisa V. Gubareva</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="RBID">pubmed:20350949</idno>
<idno type="pmid">20350949</idno>
<idno type="doi">10.1128/AAC.01739-09</idno>
<idno type="wicri:Area/PubMed/Corpus">000204</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000204</idno>
<idno type="wicri:Area/PubMed/Curation">000204</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000204</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000183</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000183</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.</title>
<author><name sortKey="Sleeman, Katrina" sort="Sleeman, Katrina" uniqKey="Sleeman K" first="Katrina" last="Sleeman">Katrina Sleeman</name>
<affiliation wicri:level="1"><nlm:affiliation>Virus Surveillance and Diagnosis Branch, Influenza Division, National Center of Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329-4018, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Virus Surveillance and Diagnosis Branch, Influenza Division, National Center of Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329-4018</wicri:regionArea>
<wicri:noRegion>GA 30329-4018</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mishin, Vasiliy P" sort="Mishin, Vasiliy P" uniqKey="Mishin V" first="Vasiliy P" last="Mishin">Vasiliy P. Mishin</name>
</author>
<author><name sortKey="Deyde, Varough M" sort="Deyde, Varough M" uniqKey="Deyde V" first="Varough M" last="Deyde">Varough M. Deyde</name>
</author>
<author><name sortKey="Furuta, Yousuke" sort="Furuta, Yousuke" uniqKey="Furuta Y" first="Yousuke" last="Furuta">Yousuke Furuta</name>
</author>
<author><name sortKey="Klimov, Alexander I" sort="Klimov, Alexander I" uniqKey="Klimov A" first="Alexander I" last="Klimov">Alexander I. Klimov</name>
</author>
<author><name sortKey="Gubareva, Larisa V" sort="Gubareva, Larisa V" uniqKey="Gubareva L" first="Larisa V" last="Gubareva">Larisa V. Gubareva</name>
</author>
</analytic>
<series><title level="j">Antimicrobial agents and chemotherapy</title>
<idno type="eISSN">1098-6596</idno>
<imprint><date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amides (pharmacology)</term>
<term>Animals</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Cell Line</term>
<term>Dogs</term>
<term>Drug Resistance, Viral</term>
<term>Humans</term>
<term>In Vitro Techniques</term>
<term>Influenza A Virus, H1N1 Subtype (drug effects)</term>
<term>Influenza A Virus, H1N1 Subtype (physiology)</term>
<term>Influenza A Virus, H2N2 Subtype (drug effects)</term>
<term>Influenza A Virus, H2N2 Subtype (physiology)</term>
<term>Influenza A Virus, H5N1 Subtype (drug effects)</term>
<term>Influenza A Virus, H5N1 Subtype (physiology)</term>
<term>Influenza A virus (drug effects)</term>
<term>Influenza A virus (physiology)</term>
<term>Influenza B virus (drug effects)</term>
<term>Influenza B virus (physiology)</term>
<term>Influenza, Human (drug therapy)</term>
<term>Influenza, Human (virology)</term>
<term>Microbial Sensitivity Tests</term>
<term>Pyrazines (pharmacology)</term>
<term>Swine</term>
<term>Viral Plaque Assay</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Amides (pharmacologie)</term>
<term>Animaux</term>
<term>Antiviraux (pharmacologie)</term>
<term>Chiens</term>
<term>Grippe humaine (traitement médicamenteux)</term>
<term>Grippe humaine (virologie)</term>
<term>Humains</term>
<term>Lignée cellulaire</term>
<term>Méthode des plages virales</term>
<term>Pyrazines (pharmacologie)</term>
<term>Réplication virale ()</term>
<term>Résistance virale aux médicaments</term>
<term>Sous-type H1N1 du virus de la grippe A ()</term>
<term>Sous-type H1N1 du virus de la grippe A (physiologie)</term>
<term>Sous-type H2N2 du virus de la grippe A ()</term>
<term>Sous-type H2N2 du virus de la grippe A (physiologie)</term>
<term>Sous-type H5N1 du virus de la grippe A ()</term>
<term>Sous-type H5N1 du virus de la grippe A (physiologie)</term>
<term>Suidae</term>
<term>Techniques in vitro</term>
<term>Tests de sensibilité microbienne</term>
<term>Virus de la grippe A ()</term>
<term>Virus de la grippe A (physiologie)</term>
<term>Virus influenza B ()</term>
<term>Virus influenza B (physiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Amides</term>
<term>Antiviral Agents</term>
<term>Pyrazines</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H2N2 Subtype</term>
<term>Influenza A Virus, H5N1 Subtype</term>
<term>Influenza A virus</term>
<term>Influenza B virus</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Amides</term>
<term>Antiviraux</term>
<term>Pyrazines</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H2N2 du virus de la grippe A</term>
<term>Sous-type H5N1 du virus de la grippe A</term>
<term>Virus de la grippe A</term>
<term>Virus influenza B</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H2N2 Subtype</term>
<term>Influenza A Virus, H5N1 Subtype</term>
<term>Influenza A virus</term>
<term>Influenza B virus</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cell Line</term>
<term>Dogs</term>
<term>Drug Resistance, Viral</term>
<term>Humans</term>
<term>In Vitro Techniques</term>
<term>Microbial Sensitivity Tests</term>
<term>Swine</term>
<term>Viral Plaque Assay</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Chiens</term>
<term>Humains</term>
<term>Lignée cellulaire</term>
<term>Méthode des plages virales</term>
<term>Réplication virale</term>
<term>Résistance virale aux médicaments</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H2N2 du virus de la grippe A</term>
<term>Sous-type H5N1 du virus de la grippe A</term>
<term>Suidae</term>
<term>Techniques in vitro</term>
<term>Tests de sensibilité microbienne</term>
<term>Virus de la grippe A</term>
<term>Virus influenza B</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Favipiravir (T-705) has previously been shown to have a potent antiviral effect against influenza virus and some other RNA viruses in both cell culture and in animal models. Currently, favipiravir is undergoing clinical evaluation for the treatment of influenza A and B virus infections. In this study, favipiravir was evaluated in vitro for its ability to inhibit the replication of a representative panel of seasonal influenza viruses, the 2009 A(H1N1) strains, and animal viruses with pandemic (pdm) potential (swine triple reassortants, H2N2, H4N2, avian H7N2, and avian H5N1), including viruses which are resistant to the currently licensed anti-influenza drugs. All viruses were tested in a plaque reduction assay with MDCK cells, and a subset was also tested in both yield reduction and focus inhibition (FI) assays. For the majority of viruses tested, favipiravir significantly inhibited plaque formation at 3.2 muM (0.5 microg/ml) (50% effective concentrations [EC(50)s] of 0.19 to 22.48 muM and 0.03 to 3.53 microg/ml), and for all viruses, with the exception of a single dually resistant 2009 A(H1N1) virus, complete inhibition of plaque formation was seen at 3.2 muM (0.5 microg/ml). Due to the 2009 pandemic and increased drug resistance in circulating seasonal influenza viruses, there is an urgent need for new drugs which target influenza. This study demonstrates that favipiravir inhibits in vitro replication of a wide range of influenza viruses, including those resistant to currently available drugs.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20350949</PMID>
<DateCompleted><Year>2010</Year>
<Month>09</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-6596</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>54</Volume>
<Issue>6</Issue>
<PubDate><Year>2010</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Antimicrobial agents and chemotherapy</Title>
<ISOAbbreviation>Antimicrob. Agents Chemother.</ISOAbbreviation>
</Journal>
<ArticleTitle>In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.</ArticleTitle>
<Pagination><MedlinePgn>2517-24</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.01739-09</ELocationID>
<Abstract><AbstractText>Favipiravir (T-705) has previously been shown to have a potent antiviral effect against influenza virus and some other RNA viruses in both cell culture and in animal models. Currently, favipiravir is undergoing clinical evaluation for the treatment of influenza A and B virus infections. In this study, favipiravir was evaluated in vitro for its ability to inhibit the replication of a representative panel of seasonal influenza viruses, the 2009 A(H1N1) strains, and animal viruses with pandemic (pdm) potential (swine triple reassortants, H2N2, H4N2, avian H7N2, and avian H5N1), including viruses which are resistant to the currently licensed anti-influenza drugs. All viruses were tested in a plaque reduction assay with MDCK cells, and a subset was also tested in both yield reduction and focus inhibition (FI) assays. For the majority of viruses tested, favipiravir significantly inhibited plaque formation at 3.2 muM (0.5 microg/ml) (50% effective concentrations [EC(50)s] of 0.19 to 22.48 muM and 0.03 to 3.53 microg/ml), and for all viruses, with the exception of a single dually resistant 2009 A(H1N1) virus, complete inhibition of plaque formation was seen at 3.2 muM (0.5 microg/ml). Due to the 2009 pandemic and increased drug resistance in circulating seasonal influenza viruses, there is an urgent need for new drugs which target influenza. This study demonstrates that favipiravir inhibits in vitro replication of a wide range of influenza viruses, including those resistant to currently available drugs.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sleeman</LastName>
<ForeName>Katrina</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Virus Surveillance and Diagnosis Branch, Influenza Division, National Center of Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329-4018, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mishin</LastName>
<ForeName>Vasiliy P</ForeName>
<Initials>VP</Initials>
</Author>
<Author ValidYN="Y"><LastName>Deyde</LastName>
<ForeName>Varough M</ForeName>
<Initials>VM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Furuta</LastName>
<ForeName>Yousuke</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Klimov</LastName>
<ForeName>Alexander I</ForeName>
<Initials>AI</Initials>
</Author>
<Author ValidYN="Y"><LastName>Gubareva</LastName>
<ForeName>Larisa V</ForeName>
<Initials>LV</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2010</Year>
<Month>03</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Antimicrob Agents Chemother</MedlineTA>
<NlmUniqueID>0315061</NlmUniqueID>
<ISSNLinking>0066-4804</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000577">Amides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EW5GL2X7E0</RegistryNumber>
<NameOfSubstance UI="C462182">favipiravir</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000577" MajorTopicYN="N">Amides</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053121" MajorTopicYN="N">Influenza A Virus, H2N2 Subtype</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053124" MajorTopicYN="N">Influenza A Virus, H5N1 Subtype</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011719" MajorTopicYN="N">Pyrazines</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010948" MajorTopicYN="N">Viral Plaque Assay</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year>
<Month>3</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2010</Year>
<Month>3</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2010</Year>
<Month>9</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">20350949</ArticleId>
<ArticleId IdType="pii">AAC.01739-09</ArticleId>
<ArticleId IdType="doi">10.1128/AAC.01739-09</ArticleId>
<ArticleId IdType="pmc">PMC2876376</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Lancet. 2000 Mar 4;355(9206):827-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10711940</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2006 Jun 15;193(12):1626-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16703504</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatr Infect Dis J. 2000 May;19(5):410-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10819336</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2001 Mar 10;322(7286):577-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11238150</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2002 Apr;46(4):977-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11897578</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2002 May 23;45(11):2207-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12014958</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2003 May 1;21(16):1796-800</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12686097</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2003 May;41(5):2164-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12734269</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2003 Aug;77(15):8418-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12857911</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antivir Chem Chemother. 2003 Sep;14(5):235-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14694986</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Saf. 1999 Oct;21(4):267-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10514019</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2005 Mar;49(3):981-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15728892</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2005 Apr;11(4 Suppl):S5-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15812490</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Anti Infect Ther. 2005 Apr;3(2):191-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15918777</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2005 Oct 20;437(7062):1108</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16228009</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2007 Mar;73(3):228-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17112602</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Pharmacol Sci. 2007 Jun;28(6):280-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17481739</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 Jun 28;25(27):5086-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17544181</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2007 Jul 15;196(2):249-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17570112</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antivir Ther. 2007;12(4):571-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17668567</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Med. 2008;59:397-413</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17939760</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2008 Jan 17;358(3):261-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18199865</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2007 Sep;13(9):1354-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18252107</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2008 Jan 31;13(5). pii: 8026</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18445375</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2008 Jun 27;57(25):692-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18583957</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2008 Sep;52(9):3284-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18625765</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2009 Jan 1;48 Suppl 1:S3-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19067613</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2009 Jan;81(1):16-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18835410</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2009 Mar 5;360(10):953-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19258250</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2009 Mar 11;301(10):1034-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19255110</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2009 Mar 11;301(10):1042-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19255111</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2009 Mar 11;301(10):1066-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19255112</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2009 Apr;15(4):552-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19331731</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2009 Apr 24;58(15):400-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19390508</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2009 May 1;58(16):433-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19407738</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2009 May 8;324(5928):705</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19423784</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2009 Jun;82(3):95-102</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19428599</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2009 May 8;58(17):467-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19444150</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2009 Jul;83(1):90-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19501261</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2009 Jun;15(6):966-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19523305</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2009 Jun 18;360(25):2605-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19423869</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2009 Jun 18;360(25):2616-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19423871</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2009 Jul;53(7):3088-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19349520</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2009 Jun 25;459(7250):1122-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19516283</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2009 Jul 10;325(5937):197-201</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19465683</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2009 Aug 20;460(7258):1021-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19672242</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2009 Aug 21;58(32):893-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19696719</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antimicrob Chemother. 2009 Oct;64(4):741-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19643775</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2009 Sep 11;58(35):969-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19745803</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2005 Nov;49(11):4515-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16251290</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2005 Dec 22;353(25):2667-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16371632</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rev Med Virol. 2000 Jan-Feb;10(1):45-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10654004</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
</list>
<tree><noCountry><name sortKey="Deyde, Varough M" sort="Deyde, Varough M" uniqKey="Deyde V" first="Varough M" last="Deyde">Varough M. Deyde</name>
<name sortKey="Furuta, Yousuke" sort="Furuta, Yousuke" uniqKey="Furuta Y" first="Yousuke" last="Furuta">Yousuke Furuta</name>
<name sortKey="Gubareva, Larisa V" sort="Gubareva, Larisa V" uniqKey="Gubareva L" first="Larisa V" last="Gubareva">Larisa V. Gubareva</name>
<name sortKey="Klimov, Alexander I" sort="Klimov, Alexander I" uniqKey="Klimov A" first="Alexander I" last="Klimov">Alexander I. Klimov</name>
<name sortKey="Mishin, Vasiliy P" sort="Mishin, Vasiliy P" uniqKey="Mishin V" first="Vasiliy P" last="Mishin">Vasiliy P. Mishin</name>
</noCountry>
<country name="États-Unis"><noRegion><name sortKey="Sleeman, Katrina" sort="Sleeman, Katrina" uniqKey="Sleeman K" first="Katrina" last="Sleeman">Katrina Sleeman</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000183 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000183 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:20350949
   |texte=   In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:20350949" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a H2N2V1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021

	Serveur d'exploration H2N2
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration H2N2

In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.

In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki